This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
October 04, 2017
GenSight Biologics to Attend Chardan Gene Therapy Conference
October 03, 2017
Targovax granted US Patent for mutant-RAS neoantigen platform 2nd generation product TG02
October 03, 2017
Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares
October 02, 2017
GenSight Biologics integrates the Enternext PEA-PME 150 index
October 02, 2017
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
October 02, 2017
Orexo signs asset purchase agreement with Gesynta Pharma AB for OX-MPI
October 01, 2017
Promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting
September 28, 2017
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
September 25, 2017
Strongbridge Biopharma plc Launches the Uncovering Periodic Paralysis Genetic Testing Program
September 25, 2017
Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics